| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
| [2] |
Samuel CA, Turner K, Donovan HAS, et al. Provider perspectives on barriers and facilitators to adjuvant endocrine therapy-related symptom management[J]. Support Care Cancer, 2017, 25(12): 3723-3731.
|
| [3] |
Hanker AB, Sudhan DR, Arteaga CL. Overcoming endocrine resistance in breast cancer[J]. Cancer Cell, 2020, 37(4): 496-513.
|
| [4] |
Jeselsohn R, Buchwalter G, De Angelis C, et al. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer[J]. Nat Rev Clin Oncol, 2015, 12(10): 573-583.
|
| [5] |
Razavi P, Chang MT, Xu G, et al. The genomic landscape of endocrine-resistant advanced breast cancers. [J]. Cancer Cell, 2018, 34(3): 427-438.
|
| [6] |
Schiavon G, Hrebien S, Garcia-Murillas I, et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer[J]. Sci Transl Med, 2015, 7(313): 313ra182.
|
| [7] |
Fribbens C, Garcia Murillas I, Beaney M, et al. Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer[J]. Ann Oncol, 2018, 29(1): 145-153.
|
| [8] |
Clatot F, Perdrix A, Beaussire L, et al. Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer[J]. Breast Cancer Res, 2020, 22(1): 56.
|
| [9] |
Zhang QX, Borg A, Wolf DM, et al. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer[J]. Cancer Res, 1997, 57(7): 1244-1249.
|
| [10] |
Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer[J]. Nat Genet, 2013, 45(12): 1446-1451.
|
| [11] |
Toy W, Shen Y, Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer[J]. Nat Genet, 2013, 45(12): 1439-1445.
|
| [12] |
Jeselsohn R, Yelensky R, Buchwalter G, et al. Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer[J]. Clin Cancer Res, 2014, 20(7): 1757-1767.
|
| [13] |
Toy W, Weir H, Razavi P, et al. Activating ESR1 mutations differentially affect the efficacy of ER antagonists[J]. Cancer Discov, 2017, 7(3): 277-287.
|
| [14] |
Hermida-Prado F, Jeselsohn R. The ESR1 mutations: from bedside to bench to bedside[J]. Cancer Res, 2021, 81(3): 537-538.
|
| [15] |
Li S, Shen D, Shao J, et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts[J]. Cell Rep, 2013, 4(6): 1116-1130.
|
| [16] |
Fribbens C, O’Leary B, Kilburn L, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer[J]. J Clin Oncol, 2016, 34(25): 2961-2968.
|
| [17] |
Kuang Y, Siddiqui B, Hu J, et al. Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer[J]. NPJ Breast Cancer, 2018, 4: 22.
|
| [18] |
Gates LA, Gu G, Chen Y, et al. Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targets[J]. Oncogene, 2018, 37(33): 4581-4598.
|
| [19] |
Turner NC, Swift C, Kilburn L, et al. ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor-positive breast cancer: A combined analysis of the phase Ⅲ SoFEA and EFECT trials[J]. Clin Cancer Res, 2020, 26(19): 5172-5177.
|
| [20] |
Jeselsohn R, De Angelis C, Brown M, et al. The evolving role of the estrogen receptor mutations in endocrine therapy-resistant breast cancer[J]. Curr Oncol Rep, 2017, 19(5): 35.
|
| [21] |
Najim O, Seghers S, Sergoynne L, et al. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials[J]. Biochim Biophys Acta Rev Cancer, 2019, 1872(2): 188 315.
|
| [22] |
De Santo I, McCartney A, Migliaccio I, et al. The emerging role of ESR1 mutations in luminal breast cancer as a prognostic and predictive biomarker of response to endocrine therapy[J]. Cancers (Basel), 2019, 11(12)：1849.
|
| [23] |
O’Leary B, Cutts RJ, Liu Y, et al. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial[J]. Cancer Discov, 2018, 8(11): 1390-1403.
|
| [24] |
Chandarlapaty S, Chen D, He W, et al. Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: A secondary analysis of the BOLERO-2 clinical trial[J]. JAMA Oncol, 2016, 2(10): 1310-1315.
|
| [25] |
Nettles KW, Bruning JB, Gil G, et al. NFkappaB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses[J]. Nat Chem Biol, 2008, 4(4): 241-247.
|
| [26] |
Gu G, Tian L, Herzog SK, et al. Hormonal modulation of ESR1 mutant metastasis[J]. Oncogene, 2021, 40(5): 997-1011.
|
| [27] |
Lefebvre C, Bachelot T, Filleron T, et al. Mutational profile of metastatic breast cancers: A retrospective analysis[J]. PLoS Med, 2016, 13(12): e1002201.
|
| [28] |
Clatot F, Perdrix A, Augusto L, et al. Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor[J]. Oncotarget, 2016, 7(46): 74448-74459.
|
| [29] |
Puyang X, Furman C, Zheng GZ, et al. Discovery of selective estrogen receptor covalent antagonists for the treatment of ERα(WT) and ERα(MUT) breast cancer[J]. Cancer Discov, 2018, 8(9): 1176-1193.
|
| [30] |
Bahreini A, Li Z, Wang P, et al. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models[J]. Breast Cancer Res, 2017, 19(1): 60.
|
| [31] |
Wardell SE, Ellis MJ, Alley HM, et al. Efficacy of SERD/SERM hybrid-CDK4/6 inhibitor combinations in models of endocrine therapy-resistant breast cancer[J]. Clin Cancer Res, 2015, 21(22): 5121-5130.
|
| [32] |
Turner NC, Kingston B, Kilburn LS, et al. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial[J]. Lancet Oncol, 2020, 21(10): 1296-1308.
|
| [33] |
Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase Ⅲ EMERALD trial[J]. J Clin Oncol, 2022, 40(28): 3246-3256.
|
| [34] |
Jimenez MM, Lim E, Gregor MC, et al. Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+，HER2- locally advanced/metastatic breast cancer (LA/mBC): primary analysis of the phase 2, randomised, open-label acelERA BC study [EB/OL]. [2022-11-25].
URL
|
| [35] |
Tolaney SM, Chan A, Petrakova K, et al. AMEERA-3, a phase 2 study of amcenestrant (AMC) versus endocrine treatment of physician’s choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2-advanced breast cancer (aBC) [EB/OL]. [2022-11-25].
URL
|
| [36] |
Goetz MP, Plourde P, Stover DG, et al. Open-label, randomized study of lasofoxifene (LAS) vs fulvestrant (Fulv) for women with locally advanced/metastatic ER+/HER2- breast cancer (mBC), an estrogen receptor 1 (ESR1) mutation, and disease progression on aromatase (AI) and cyclin-dependent kinase 4/6 (CDK4/6i) inhibitors [EB/OL]. [2022-11-25].
URL
|
| [37] |
Damodaran S, Plourde PV, Moore HCF, et al. Open-label, phase 2, multicenter study of lasofoxifene (LAS) combined with abemaciclib (Abema) for treating pre- and postmenopausal women with locally advanced or metastatic ER+/HER2-breast cancer and an ESR1 mutation after progression on prior therapies[J]. J Clin Oncol, 2022, 40(16_suppl): 1022-1022.
|
| [38] |
Furman C, Puyang X, Zhang Z, et al. Covalent ERα antagonist H3B-6545 demonstrates encouraging preclinical activity in therapy-resistant breast cancer[J]. Mol Cancer Ther, 2022, 21(6): 890-902.
|
| [39] |
Narasimha AM, Kaulich M, Shapiro GS, et al. Cyclin D activates the Rb tumor suppressor by mono-phosphorylation[J]. Elife, 2014, 3: e02872.
|
| [40] |
Wander SA, Cohen O, Gong X, et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer[J]. Cancer Discov, 2020, 10(8): 1174-1193.
|
| [41] |
Bidard FC, Hardy-Bessard AC, Dalenc F, et al. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet Oncol, 2022, 23(11): 1367-1377.
|
| [42] |
Tolaney SM, Toi M, Neven P, et al. Clinical significance of PIK3CA and ESR1 mutations in circulating tumor DNA: Analysis from the MONARCH 2 study of abemaciclib plus fulvestrant[J]. Clin Cancer Res, 2022, 28(8): 1500-1506.
|
| [43] |
Moore HM, Savage HM, O’Brien C, et al. Predictive and pharmacodynamic biomarkers of response to the phosphatidylinositol 3-kinase inhibitor taselisib in breast cancer preclinical models[J]. Mol Cancer Ther, 2020, 19(1): 292-303.
|
| [44] |
Razavi P, Dickler MN, Shah PD, et al. Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors[J]. Nat Cancer, 2020, 1(4): 382-393.
|
| [45] |
Bardia A, Hurvitz SA, Demichele A, et al. Phase Ⅰ/Ⅱ trial of exemestane, ribociclib, and everolimus in women with HR(+)/HER2(－) advanced breast cancer after progression on CDK4/6 inhibitors (TRINITI-1)[J]. Clin Cancer Res, 2021, 27(15): 4177-4185.
|
| [46] |
Ladd B, Mazzola AM, Bihani T, et al. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations[J]. Oncotarget, 2016, 7(34): 54 120-54 136.
|